• 340B Insider – March 2016

    Welcome to the March edition of RxStrategies 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view. 340B UNIVERSITY UPDATES Recently, the RxStrategies experts attended 340B University, presented by Apexus, to gain further insight regarding current 340B trends.  The following are highlights from a recent session: 1.) 340B Mega Guidance: Over 1300… Read more »

  • Connect with RxStrategies During the NACHC’s 2016 Policy & Issues Forum

    RxStrategies will be attending the NACHC’s 2016 Policy & Issues Forum from March 16 – 19.  Rhodie Smith and the RxStrategies’ team are looking forward to connecting with health cen­ter lead­ers and decision-makers and pub­lic health leaders in the heart of Wash­ing­ton, D.C. to focus on the nation’s health­care. During the meeting, they will be… Read more »

  • RxStrategies Appoints Sales Manager – Northeast Region

    BOCA RATON, Florida, March 3, 2016 – RxStrategies, Inc. is pleased to announce the appointment of Russell Crane to the new position of Sales Manager – Northeast Region. He joins the RxStrategies’ sales team and has responsibility for sales and delivery of customized 340B pharmacy administration and split billing solutions to providers located in the… Read more »

  • Clinical Insights — March 2016 Issue

    Welcome to the March edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Briviact® (brivaracetam)  February 19, 2016 – The U.S. Food and Drug Administration (FDA) approved Briviact® (brivaracetam) as an add-on treatment to other medications to treat partial onset… Read more »

  • Connect with RxStrategies During the OACHC 2016 Annual Conference

        RxStrategies will be attending the Ohio Association of Community Health Centers 2016 Annual Conference from February 29 to March 2.  Our team is looking forward to connecting with FQCHC leaders in Ohio to discuss 340B comprehensive solutions to the challenges of regulatory compliance, patient eligibility, pharmacy replenishment, program tracking and reporting of the… Read more »

  • Proud Pinnacle Leader Sponsor of the 12th Annual 340B Coalition Winter Conference

    The best way to stay abreast of 340B happenings is to attend the12th Annual 340B Coalition Winter Conference, taking place February 17 to 19 in San Diego, CA. During the conference our team will network with industry leaders to discuss HRSA’s proposed mega-guidance and gain further insight on issues impacting the overall market. Learn more. RxStrategies is proud to… Read more »

  • Clinical Insights — January Issue 2

    Welcome to the second January edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Formulation Approval Humulin® R KwikPen® (insulin human injection) – New Formulation Approval January 21, 2016 – The U.S. Food and Drug Administration approved Eli Lilly and Company’s Humulin®… Read more »

  • Clinical Insights — January Issue 1

    Welcome to the first January edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.     New Drug Approval Zurampic® (lesinurad) December 22, 2015 – The U.S. Food and Drug Administration approved Zurampic® (lesinurad) to treat high levels of uric acid in the blood… Read more »

  • December 340B Insider

    Welcome to the December edition of RxStrategies 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.   Highlights from ASHP Midyear Clinical Meeting This month, the RxStrategies’ team was pleased to participate in ASHP’s Midyear Clinical Meeting and Exhibition, one of the largest gatherings of pharmacists in the world. A Few… Read more »